"The voice for cancer physicians and their patients in Massachusetts."
The U.S. Food and Drug Administration approved cabozantinib (Cabometyz; Exelixis) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Read full press release.
© Copyright. All rights reserved.
Massachusetts Society of Clinical Oncologists
P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: email@example.com